901119-38-8

Usage

Uses

Used in Pharmaceutical Industry:
Ditert-butyl [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxo-pyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate is used as a potential pharmaceutical candidate for drug development due to its complex structure and functional groups.
Used in Molecular Biology Research:
Ditert-butyl [6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxo-pyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate is used as a research tool in molecular biology to study its potential interactions with biological systems and understand its properties.
Further investigation and research are needed to fully understand the potential uses and properties of this chemical.

Upstream product

• 841290-80-0 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one 
• 229625-50-7 di-tert-butyl chloromethyl phosphate 
• 33494-80-3 potassium di-tert-butylphosphate 
• 575484-83-2 6-[(2-chloro-5-fluoro-pyrimidin-4-yl)amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one 

Downstream Products

• 841290-80-0 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one 
• 901119-35-5 fostamatinib 

Relevant academic research and scientific papers

METHOD OF BLOCKING OR AMELIORATING CYTOKINE RELEASE SYNDROME

Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a Syk inhibitor, and/or may have a structure according to Formula I. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.

Pharmaceutical Process and Intermediates

The present disclosure provides for processes and intermediates in the large-scale manufacture of the compound of formula (I) or hydrates thereof.

Synthesis of 2,4-Pyrimidinediamines

Disclosed herein are methods for synthesizing 2,4-pyrimidinediamines as well as intermediates used therein.

Methods of Treating Cell Proliferative Disorders

The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a RET kinase inhibitor. Cell proliferative disorders treatable by the methods include, thyroid tumors.

PRODRUG SALTS OF 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES

The present disclosure provides prodrugs of biologically active 2,4- pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions. comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications. In particular the claims relate to salts of the phosphate ester of the following structure:

PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES

The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.